Turing Biosystems

About Turing Biosystems

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

```xml <problem> Immunotherapy and cell & gene therapy face challenges with high failure rates and adverse immune responses. Analyzing patient responses to therapy and designing better treatments is difficult due to the complexity of integrating multimodal clinical and biological data. Current methods struggle to effectively manage this complexity, hindering the development of safer and more effective personalized treatments. </problem> <solution> Turing Biosystems offers a software platform that leverages interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data. The platform connects various data types, including metadata, health records, multi-omics, tissue and imaging data, public data, and prior knowledge, to analyze patient responses to therapy and design improved treatments. By focusing on clinical outcomes optimization, the platform aims to enhance the safety and efficacy of therapies for patients, clinicians, and biopharma. The AI provides an evidence chain for its conclusions, empowering scientists and clinicians in their decision-making process. </solution> <features> - Interpretable AI built on automated reasoning to reproduce human thought processes - Graph-based integration of multimodal data, including multi-omics, imaging, and clinical records - AI reasoning audit trail to understand the evidence behind outputs - Spatial biology module to analyze and simulate multiscale biology - Bioinformatics R&D tools and pipelines, with support for Nextflow - Graph engine (TuringDB.ai) for integrating complex biological data - Integration with existing tools and frameworks, such as Jupyter Notebooks, VS Code, and Neo4J </features> <target_audience> The primary users are clinicians and biopharmaceutical companies involved in immunotherapy and cell & gene therapy, seeking to improve clinical outcomes and develop more effective, personalized treatments. </target_audience> ```

What does Turing Biosystems do?

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

Where is Turing Biosystems located?

Turing Biosystems is based in London, United Kingdom.

When was Turing Biosystems founded?

Turing Biosystems was founded in 2023.

Who founded Turing Biosystems?

Turing Biosystems was founded by Rémy Boutonnet and Adam Amara.

  • Rémy Boutonnet - Co-Founder/Computer scientist
  • Adam Amara - Co-Founder
Location
London, United Kingdom
Founded
2023
Employees
9 employees
Major Investors
Haatch
Looking for specific startups?
Try our free semantic startup search

Turing Biosystems

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

turing.bio1K+
cb
Crunchbase
Founded 2023London, United Kingdom

Funding

Major Investors

Haatch

Team (5+)

Rémy Boutonnet

Co-Founder/Computer scientist

Adam Amara

Co-Founder

Company Description

Problem

Immunotherapy and cell & gene therapy face challenges with high failure rates and adverse immune responses. Analyzing patient responses to therapy and designing better treatments is difficult due to the complexity of integrating multimodal clinical and biological data. Current methods struggle to effectively manage this complexity, hindering the development of safer and more effective personalized treatments.

Solution

Turing Biosystems offers a software platform that leverages interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data. The platform connects various data types, including metadata, health records, multi-omics, tissue and imaging data, public data, and prior knowledge, to analyze patient responses to therapy and design improved treatments. By focusing on clinical outcomes optimization, the platform aims to enhance the safety and efficacy of therapies for patients, clinicians, and biopharma. The AI provides an evidence chain for its conclusions, empowering scientists and clinicians in their decision-making process.

Features

Interpretable AI built on automated reasoning to reproduce human thought processes

Graph-based integration of multimodal data, including multi-omics, imaging, and clinical records

AI reasoning audit trail to understand the evidence behind outputs

Spatial biology module to analyze and simulate multiscale biology

Bioinformatics R&D tools and pipelines, with support for Nextflow

Graph engine (TuringDB.ai) for integrating complex biological data

Integration with existing tools and frameworks, such as Jupyter Notebooks, VS Code, and Neo4J

Target Audience

The primary users are clinicians and biopharmaceutical companies involved in immunotherapy and cell & gene therapy, seeking to improve clinical outcomes and develop more effective, personalized treatments.

Turing Biosystems | StartupSeeker